Related Experiment Video
Updated: Oct 6, 2025
Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
Published on: April 10, 2020
Zebrafish Xenograft Model to Study Human Cancer
Ranganatha R Somasagara1, TinChung Leung2,3
1The Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, North Carolina Research Campus, Kannapolis, NC, USA.
Abstract:
The zebrafish, Danio rerio, has been an important animal model for cancer research over the last decade. The capability of a high-throughput screen in zebrafish and a wide range of pharmacologically active compounds elicit physiological responses in zebrafish embryos comparable to those in mammalian systems, making zebrafish ideal for identifying clinically relevant drug targets and compounds that regulate tumor progression. The zebrafish model is suitable for patient-derived xenograft (pdx) and large-scale screening of lead compounds against specific malignancies. This established vertebrate model has many advantages, including fast response time, cost efficiency for drug testing, efficient manipulation of the host microenvironment by genetic tools, suitable for small molecule drug screening in high-throughput setting, easy maintenance, transparency for easy observation, high fecundity, and rapid generation time. The zebrafish model is a good alternative in vivo model to mammals for robust testing of drug candidates for cancer therapy.
Insights
Zebrafish embryos offer a powerful, cost-effective model for cancer research. Their rapid development and transparency enable high-throughput screening of potential cancer drugs, serving as a viable alternative to mammalian models.
Area of Science:
- Comparative oncology
- Translational research
- Pharmacology
Background:
- The zebrafish (Danio rerio) has emerged as a significant animal model in cancer research.
- Its physiological responses to compounds mirror mammalian systems, facilitating drug target identification.
Purpose of the Study:
- To highlight the utility of zebrafish as a model for cancer drug discovery and development.
- To emphasize its advantages for high-throughput screening and patient-derived xenograft studies.
Main Methods:
- Leveraging zebrafish for high-throughput screening of pharmacologically active compounds.
- Utilizing genetic tools for manipulating the host microenvironment.
- Employing zebrafish for patient-derived xenograft (PDX) models.
Main Results:
- Zebrafish embryos exhibit drug responses comparable to mammalian systems.
- The model supports large-scale screening of lead compounds against various malignancies.
- Advantages include cost-efficiency, rapid generation time, and ease of observation.
Conclusions:
- Zebrafish represent a robust and efficient in vivo alternative to mammals for testing cancer therapeutics.
- The model accelerates the identification of clinically relevant drug targets and compounds regulating tumor progression.
